Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors

Published:2020-06 Issue:2 Volume:1 Page:100017
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Kasparian Saro^ORCID,Gentille Cesar,Burns Ethan,Bernicker Eric H.

Publisher

Elsevier BV

Reference11 articles.

1. Patterns of response and progression to immunotherapy;Borcoman;Am Soc Clin Oncol Educ Book,2018

2. Hyperprogression with immunotherapy: is it real?;Popat;Cancer,2019

3. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012

4. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1;Champiat;Clin Cancer Res,2017

5. Hyperprogressive disease in early-phase immunotherapy trials: clinical predictors and association with immune-related toxicities;Kanjanapan;Cancer,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP